Brainstorm Cell Therapeutics Inc. (BCLI) Financial Analysis & Valuation | Quarter Chart
Brainstorm Cell Therapeutics Inc. (BCLI)
BCLIPrice: $0.67
Fair Value: 🔒
🔒score
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce a... more
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercia... more
Description
Shares
| Market Cap | $6.95M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Chaim Lebovits |
| IPO Date | 2003-10-07 | CAGR | 0.18% |
| Employees | 27 | Website | www.brainstorm-cell.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BCLI chart loading...
Fundamentals
Technicals
| Enterprise Value | $9.41M | P/E Ratio | — |
| Forward P/E | -0.99 | PEG Ratio | — |
| P/S Ratio | 8.19 | P/B Ratio | -0.95 |
| P/CF Ratio | -0.61 | P/FCF Ratio | -0.73 |
| EPS | $-1.73 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 147.52% | Gross Margin | 0.61% |
| Operating Margin | -14.02% | Profit Margin | -13.48% |
| ROE | 1.68% | ROA | -4.46% |
| ROCE | 2% | Current Ratio | 0.18 |
| Quick Ratio | 0.18 | Cash Ratio | 0.1 |
| Debt/Equity | -0.1 | Interest Coverage | -180.29 |
| Altman Z Score | -144.58 | Piotroski Score | 2 |